--- title: "Roivant Sciences (NASDAQ:ROIV) Insider Sells 284,707 Shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/296330990.md" description: "Roivant Sciences insider Mayukh Sukhatme sold 284,707 shares on August 17 at an average price of $36.25, totaling over $10.3 million. This transaction reduced his direct holdings by 1.51%, leaving him with 18,630,739 shares valued at approximately $675.4 million. The sale was disclosed via an SEC filing." datetime: "2026-08-19T09:22:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296330990.md) - [en](https://longbridge.com/en/news/296330990.md) - [zh-HK](https://longbridge.com/zh-HK/news/296330990.md) generator: "portal-rs" --- # Roivant Sciences (NASDAQ:ROIV) Insider Sells 284,707 Shares Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 284,707 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the transaction, the insider directly owned 18,630,739 shares of the company's stock, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. - Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching Mayukh Sukhatme also recently made the following trade(s): - On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71. - On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66. ## Roivant Sciences Stock Performance Roivant Sciences stock opened at $37.37 on Wednesday. The business's 50-day simple moving average is $34.16 and its 200-day simple moving average is $30.17. The firm has a market capitalization of $26.99 billion, a PE ratio of -70.51 and a beta of 1.12. Roivant Sciences Ltd. has a 52 week low of $11.54 and a 52 week high of $37.46. * * * * * * Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million during the quarter, compared to analysts' expectations of $2.06 million. Research analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year. ## Analyst Ratings Changes A number of brokerages have recently commented on ROIV. Weiss Ratings lowered Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, May 22nd. Bank of America reaffirmed a "neutral" rating on shares of Roivant Sciences in a research report on Friday, July 31st. Guggenheim upped their target price on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Piper Sandler reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, TD Cowen restated a "buy" rating on shares of Roivant Sciences in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $35.14. **Check Out Our Latest Report on Roivant Sciences** ## Hedge Funds Weigh In On Roivant Sciences Several large investors have recently added to or reduced their stakes in ROIV. Morgan Stanley lifted its position in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Vanguard Group Inc. grew its holdings in shares of Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company's stock worth $912,681,000 after purchasing an additional 3,254,113 shares in the last quarter. Rubric Capital Management LP increased its position in shares of Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the period. State Street Corp increased its position in shares of Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company's stock valued at $222,847,000 after purchasing an additional 911,827 shares during the period. Finally, UBS Group AG raised its stake in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company's stock valued at $399,080,000 after purchasing an additional 15,645,836 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock. ## About Roivant Sciences (Get Free Report) Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines. The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health. ## Featured Stories - Five stocks we like better than Roivant Sciences - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at Roivant Sciences? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Roivant Sciences and related companies. From Our Partners ALERT: Drop these 5 stocks before the market opens tomorrow! The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc... Weiss Ratings Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top... InvestorPlace Ready to give options a try? Your first trade (Ticker included) -INSIDE Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st... Base Camp Trading Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c... Altimetry Iran War Shock: What I Was Told In That Private Meeting You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th... Banyan Hill Publishing My top 3 AI picks for the next decade Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A... The Oxford Club Buy this stock today Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo... Chaikin Analytics Here’s the stock symbol I’ve promised Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b... Stansberry Research ### Related Stocks - [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [STT.US](https://longbridge.com/en/quote/STT.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) - [SPIN.US](https://longbridge.com/en/quote/SPIN.US.md) ## Related News & Research - [Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock](https://longbridge.com/en/news/296663712.md) - [Roivant Sciences President & CIO Sold Shares Worth Over $24M](https://longbridge.com/en/news/296285296.md) - [How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly Revenue](https://longbridge.com/en/news/296027733.md) - [Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares](https://longbridge.com/en/news/296284164.md) - [Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 million](https://longbridge.com/en/news/296660931.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**